| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 5. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | tafluprost/timolol (Taptiqom®) |
| Formulation | 15 micrograms per ml/5 mg per ml eye drops |
| Reference number | 2538 |
| Indication | Reduction of intraocular pressure in adult patients with open angle glaucoma or ocular hypertension who are insufficiently responsive to topical monotherapy with beta-blockers or prostaglandin analogues and require a combination therapy, and who would benefit from preservative free eye drops |
| Company | Santen Pharmaceutical |
| BNF chapter | Eye |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 29/07/2015 |